Johnson & Johnson: Vanguard Group Biggest Healthcare Stock Position in Q3

Wall St. Watchdog reveals information regarding Vanguard Group, Inc.’s top holdings in the Healthcare sector for the quarter ending September 30th, 2011. The firm held 433 stocks in the Healthcare sector at the end of the quarter with an aggregate market value of $57.605 billion.

  • Johnson & Johnson (NYSE:JNJ): On 06/30/2011, Vanguard Group, Inc. reported holding 103,776,159 shares with a market value of $6,903,189,748. This comprised 1.06% of the total portfolio. On 09/30/2011, Vanguard Group, Inc. reported holding 106,426,119 shares with a market value of $6,778,279,373. This comprised 1.21% of the total portfolio. The net change in shares for this position over the two quarters is 2,649,960. About Company: Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
  • Pfizer Inc. (NYSE:PFE): On 06/30/2011, Vanguard Group, Inc. reported holding 301,711,138 shares with a market value of $6,215,249,558. This comprised 0.96% of the total portfolio. On 09/30/2011, Vanguard Group, Inc. reported holding 306,268,813 shares with a market value of $5,414,832,707. This comprised 0.97% of the total portfolio. The net change in shares for this position over the two quarters is 4,557,675. About Company: Pfizer Inc. is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. The Company’s products include prescription pharmaceuticals, non-prescription self-medications, and animal health products such as anti-infective medicines and vaccines.
  • Merck & Co. Inc. (NYSE:MRK): On 06/30/2011, Vanguard Group, Inc. reported holding 117,090,455 shares with a market value of $4,132,122,264. This comprised 0.64% of the total portfolio. On 09/30/2011, Vanguard Group, Inc. reported holding 120,224,095 shares with a market value of $3,931,327,998. This comprised 0.7% of the total portfolio. The net change in shares for this position over the two quarters is 3,133,640. About Company: Merck & Co., Inc. is a global pharmaceutical company that discovers, develops, manufactures, and markets a broad range of human and animal health products. Merck’s products include a treatment for elevated cholesterol, a treatment for male pattern hair loss, a preventive treatment for osteoporosis, a treatment for hypertension, and a treatment for allergic rhinitis.
  • Abbott Laboratories (NYSE:ABT): On 06/30/2011, Vanguard Group, Inc. reported holding 58,549,510 shares with a market value of $3,080,875,154. This comprised 0.47% of the total portfolio. On 09/30/2011, Vanguard Group, Inc. reported holding 60,547,693 shares with a market value of $3,096,408,983. This comprised 0.55% of the total portfolio. The net change in shares for this position over the two quarters is 1,998,183. About Company: Abbott Laboratories discovers, develops, manufactures, and sells a broad and diversified line of health care products and services. The Company’s products include pharmaceuticals, nutritional, diagnostics, and vascular products. Abbott markets its products worldwide through affiliates and distributors.
  • Bristol-myers Squibb Company (NYSE:BMY): On 06/30/2011, Vanguard Group, Inc. reported holding 65,181,093 shares with a market value of $1,887,644,394. This comprised 0.29% of the total portfolio. On 09/30/2011, Vanguard Group, Inc. reported holding 67,104,753 shares with a market value of $2,105,747,093. This comprised 0.38% of the total portfolio. The net change in shares for this position over the two quarters is 1,923,660. About Company: Bristol-Myers Squibb Company is a global biopharmaceutical company that discovers, develops, manufactures and sells pharmaceutical and nutritional products. The Company’s products and experimental therapies address cancer, heart disease, HIV/AIDS, diabetes, rheumatoid arthritis, hepatitis, organ transplant rejection and psychiatric disorders.
  • Unitedhealth Group Inc. (NYSE:UNH): On 06/30/2011, Vanguard Group, Inc. reported holding 42,066,581 shares with a market value of $2,169,794,325. This comprised 0.33% of the total portfolio. On 09/30/2011, Vanguard Group, Inc. reported holding 42,800,012 shares with a market value of $1,973,936,508. This comprised 0.35% of the total portfolio. The net change in shares for this position over the two quarters is 733,431. About Company: UnitedHealth Group Incorporated owns and manages organized health systems in the United States and internationally. The Company provides employers products and resources to plan and administer employee benefit programs. UnitedHealth also serves the health needs of older Americans, provides specialized care services, and provides health care information and research to providers and payers.
  • Amgen Inc. (NASDAQ:AMGN): On 06/30/2011, Vanguard Group, Inc. reported holding 35,249,925 shares with a market value of $2,056,833,070. This comprised 0.32% of the total portfolio. On 09/30/2011, Vanguard Group, Inc. reported holding 35,803,623 shares with a market value of $1,967,767,087. This comprised 0.35% of the total portfolio. The net change in shares for this position over the two quarters is 553,698. About Company: Amgen Inc. discovers, develops, manufactures, and markets human therapeutics based on cellular and molecular biology. The Company focuses its research on secreted protein and small molecule therapeutics, with particular emphasis on neuroscience and cancer. Amgen concentrates on the areas of hematology, cancer, infectious disease, endocrinology, neurobiology, and inflammation.
  • Medtronic Inc. (NYSE:MDT): On 06/30/2011, Vanguard Group, Inc. reported holding 45,954,033 shares with a market value of $1,770,608,835. This comprised 0.27% of the total portfolio. On 09/30/2011, Vanguard Group, Inc. reported holding 47,411,654 shares with a market value of $1,575,963,459. This comprised 0.28% of the total portfolio. The net change in shares for this position over the two quarters is 1,457,621. About Company: Medtronic, Inc. develops therapeutic and diagnostic medical products. The Company’s principal products include those for bradycardia pacing, tachyarrhythmia management, atrial fibrillation management, heart failure management, heart valve replacement, malignant and non-malignant pain, and movement disorders. Medtronic’s products are sold worldwide.
  • Eli Lilly & Co. (NYSE:LLY): On 06/30/2011, Vanguard Group, Inc. reported holding 39,461,272 shares with a market value of $1,480,981,490. This comprised 0.23% of the total portfolio. On 09/30/2011, Vanguard Group, Inc. reported holding 40,650,175 shares with a market value of $1,502,837,019. This comprised 0.27% of the total portfolio. The net change in shares for this position over the two quarters is 1,188,903. About Company: Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products for humans and animals. The Company’s products are sold in countries around the world. Eli Lilly’s products include neuroscience products, endocrine products, anti-infectives, cardiovascular agents, oncology products, and animal health products.
  • Baxter International Inc. (NYSE:BAX): On 06/30/2011, Vanguard Group, Inc. reported holding 22,535,389 shares with a market value of $1,345,137,338. This comprised 0.21% of the total portfolio. On 09/30/2011, Vanguard Group, Inc. reported holding 22,884,999 shares with a market value of $1,284,763,830. This comprised 0.23% of the total portfolio. The net change in shares for this position over the two quarters is 349,610. About Company: Baxter International Inc. develops, manufactures, and markets products and technologies related to hemophilia, immune disorders, infectious diseases, kidney disease, trauma and other chronic and acute medical conditions. The Company’s products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors’ offices, and research laboratories.

(Note: Data regarding Vanguard Group, Inc.’s stock holdings are sourced from whalewisdom.com. All data are assumed to be accurate.)

Advantage: Check out our interactive stock charts, fundamentals, Twitter stream, and more >>

Improve Your 2011 Financial Health: Join the winning team of stock pickers with Wall St. Cheat Sheet’s acclaimed premium newsletter>>